Pierre Van Damme

Summary

Affiliation: University of Antwerp
Country: Belgium

Publications

  1. ncbi request reprint Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, Faculty of Medicine, University of Antwerp, Universiteitsplein, 1 B 2610 Antwerp, Belgium
    Vaccine 22:305-8. 2004
  2. ncbi request reprint A review of the long-term protection after hepatitis A and B vaccination
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Belgium
    Travel Med Infect Dis 5:79-84. 2007
  3. pmc Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model
    Eva Lefevere
    Herman Deleeck Centre for Social Policy, Antwerp University, St Jacobstraat 2, 2000 Antwerpen, Belgium
    BMC Public Health 11:470. 2011
  4. pmc Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
    Robbin Itzler
    Merck Research Laboratories, West Point, Pennsylvania, USA
    BMC Pediatr 10:42. 2010
  5. pmc How to optimise the coverage rate of infant and adult immunisations in Europe
    Heinz J Schmitt
    Infectious Diseases Service at the Zentrum für Präventive Pädiatrie, Johannes Gutenberg Universitat, Mainz, Germany
    BMC Med 5:11. 2007
  6. pmc Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium
    Niel Hens
    Interuniversity Institute for Biostatistics and Statistical Bioinformatics I BioStat, Hasselt University and Catholic University of Leuven, Agoralaan 1, 3590 Diepenbeek, Belgium
    BMC Infect Dis 9:5. 2009
  7. doi request reprint Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine
    P Van Damme
    Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination WHO Collaborating Centre Campus Drie Eiken, Universiteitsplein 1, Antwerpen, Belgium
    J Med Virol 84:11-7. 2012
  8. pmc Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study
    Pierre Van Damme
    University of Antwerp, Wilrijk, Belgium
    BMC Infect Dis 10:134. 2010
  9. ncbi request reprint Hepatitis A booster vaccination: is there a need?
    P Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Control and Prevention of Viral Hepatitis, Unit of Epidemiology and Social Medicine, University of Antwerp, 2610, Antwerp, Belgium
    Lancet 362:1065-71. 2003
  10. ncbi request reprint A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine
    Pierre Van Damme
    Unit of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Campus 3 Eiken, Wilrijk, Belgium
    Expert Rev Vaccines 3:249-67. 2004

Detail Information

Publications104 found, 100 shown here

  1. ncbi request reprint Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, Faculty of Medicine, University of Antwerp, Universiteitsplein, 1 B 2610 Antwerp, Belgium
    Vaccine 22:305-8. 2004
    ....
  2. ncbi request reprint A review of the long-term protection after hepatitis A and B vaccination
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Belgium
    Travel Med Infect Dis 5:79-84. 2007
    ....
  3. pmc Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model
    Eva Lefevere
    Herman Deleeck Centre for Social Policy, Antwerp University, St Jacobstraat 2, 2000 Antwerpen, Belgium
    BMC Public Health 11:470. 2011
    ..During this period the initiative for vaccination was taken by the girl, her family or the general practitioner/pediatrician/gynecologist...
  4. pmc Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
    Robbin Itzler
    Merck Research Laboratories, West Point, Pennsylvania, USA
    BMC Pediatr 10:42. 2010
    ..The paper also explores the consistency of the results for different subgroups of the study population with different types of surveillance...
  5. pmc How to optimise the coverage rate of infant and adult immunisations in Europe
    Heinz J Schmitt
    Infectious Diseases Service at the Zentrum für Präventive Pädiatrie, Johannes Gutenberg Universitat, Mainz, Germany
    BMC Med 5:11. 2007
    ..Although vaccination has been proved to be a safe, efficacious, and cost-effective intervention, immunisation rates remain suboptimal in many European countries, resulting in poor control of many vaccine-preventable diseases...
  6. pmc Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium
    Niel Hens
    Interuniversity Institute for Biostatistics and Statistical Bioinformatics I BioStat, Hasselt University and Catholic University of Leuven, Agoralaan 1, 3590 Diepenbeek, Belgium
    BMC Infect Dis 9:5. 2009
    ..In contrast to other European surveys conducted simultaneously, each respondent recorded contacts over two days. Special attention was given to holiday periods, and respondents with large numbers of professional contacts...
  7. doi request reprint Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine
    P Van Damme
    Vaccine and Infectious Disease Institute, Centre for the Evaluation of Vaccination WHO Collaborating Centre Campus Drie Eiken, Universiteitsplein 1, Antwerpen, Belgium
    J Med Virol 84:11-7. 2012
    ....
  8. pmc Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study
    Pierre Van Damme
    University of Antwerp, Wilrijk, Belgium
    BMC Infect Dis 10:134. 2010
    ..The immunogenicity of an intradermal seasonal influenza vaccine was compared with that of an adjuvanted vaccine in the elderly...
  9. ncbi request reprint Hepatitis A booster vaccination: is there a need?
    P Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Control and Prevention of Viral Hepatitis, Unit of Epidemiology and Social Medicine, University of Antwerp, 2610, Antwerp, Belgium
    Lancet 362:1065-71. 2003
    ..However, further investigations are needed before deciding if boosters can be omitted in special patient-groups...
  10. ncbi request reprint A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine
    Pierre Van Damme
    Unit of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Campus 3 Eiken, Wilrijk, Belgium
    Expert Rev Vaccines 3:249-67. 2004
    ..This paper provides a critical review of clinical data on the efficacy, immunogenicity and tolerability of the combined vaccine, with particular focus on the clinical benefits of dual vaccination...
  11. ncbi request reprint Combining hepatitis A and B vaccination in children and adolescents
    P Van Damme
    Center for the Evaluation of Vaccination, WHO Collaborating Centre, Department of Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium
    Vaccine 19:2407-12. 2001
    ..Current results indicate that this two-dose schedule of the adult formulation could be considered a viable alternative for immunization of children and adolescents...
  12. ncbi request reprint Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study
    Pierre Van Damme
    Faculty of Medicine, Centre for the Evaluation of Vaccination, World Health Organization Collaborating Centre for the Control and Prevention of Viral Hepatitis, University of Antwerp, Antwerp, Antwerp, BE 2610, Belgium
    J Infect Dis 195:S4-S16. 2007
    ..Rotavirus is recognized as a significant cause of pediatric gastroenteritis worldwide. Comprehensive data on the burden of rotavirus disease in Europe were lacking...
  13. ncbi request reprint Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults
    P Van Damme
    Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium
    J Med Virol 65:6-13. 2001
    ..The combined hepatitis A and B vaccine is safe and is well tolerated. Immunity provided by the vaccine remains high in adults and children with comparable results to those obtained with monovalent vaccines...
  14. ncbi request reprint Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL Study
    Pierre Van Damme
    Faculty of Medicine, Centre for the Evaluation of Vaccination, World Health Organization Collaborating Centre for the Control and Prevention of Viral Hepatitis, University of Antwerp, Antwerp, BE 2610, Belgium
    J Infect Dis 195:S17-25. 2007
    ..Rotavirus gastroenteritis (RVGE) constitutes a significant burden of pediatric disease. Knowledge of currently cocirculating rotavirus genotypes is required to help guide immunization strategies...
  15. doi request reprint Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute WHO Collaborating Centre, University of Antwerp, Antwerpen, Belgium
    Pediatr Infect Dis J 30:703-5. 2011
    ..All subjects with anti-HBs concentrations <10 mIU/mL, mounted a vigorous anamnestic response to an HBV vaccine challenge dose indicating the presence of immunologic memory against hepatitis B...
  16. pmc Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study
    Pierre Van Damme
    Faculty of Medicine, Vaccine and Infectious Disease Institute WHO Collaborating Centre, Centre for Evaluation of Vaccination, Antwerpen, Belgium
    BMC Infect Dis 10:357. 2010
    ..This follow-up study evaluated the five year persistence of antibody response and immune memory against the hepatitis B surface (anti-HBs) antigens five years after completion of primary vaccination...
  17. ncbi request reprint Rotavirus vaccines: considerations for successful implementation in Europe
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, University of Antwerp, Belgium
    Lancet Infect Dis 6:805-12. 2006
    ..Further studies on the cost of the disease and the benefit of vaccination, together with raising awareness are necessary steps to ensure successful implementation of rotavirus vaccination in Europe...
  18. doi request reprint Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium
    Heidi Theeten
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, B 2610 Antwerp, Belgium
    Acta Paediatr 98:1307-12. 2009
    ..Meningococcal serogroup C and DT-polio vaccines offered respectively as catch-up and booster vaccinations were also evaluated...
  19. doi request reprint Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium
    Heidi Theeten
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, B 2610 Antwerp, Belgium
    Vaccine 27:1964-9. 2009
    ..Work-loss due to vaccination was assessed for infants only and was rare (4.5%)...
  20. doi request reprint Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium
    Joke Bilcke
    Centre for Health Economics and Modelling Infectious Diseases, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
    Med Decis Making 29:33-50. 2009
    ..To estimate the cost-effectiveness of universal childhood rotavirus vaccination in Belgium, taking into account the impact of caregiver burden and the burden of sick children for whom no medical care is sought ("no medical care'' )...
  21. doi request reprint The health and economic burden of rotavirus disease in Belgium
    Joke Bilcke
    Unit for Health Economics and Modelling Infectious Diseases, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Eur J Pediatr 167:1409-19. 2008
    ..This burden is estimated to represent direct costs of 7.7 million Euro and indirect costs of 12.8 million Euro. Rotavirus disease causes a substantial health and economic burden in Belgium...
  22. doi request reprint Caregivers' willingness to pay to reduce the number of vaccine injections in infants
    Heidi Theeten
    Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 28:61-3. 2009
    ..These results suggest that more sophisticated methods are required, and similar analyses should exert a similar level of caution when presenting their results...
  23. ncbi request reprint Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey
    Koen Van Herck
    WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Unit of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium
    J Travel Med 11:3-8. 2004
    ..This paper describes the methods used everywhere, and results from the European airports...
  24. doi request reprint Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery
    Greet Hendrickx
    Viral Hepatitis Prevention Board, Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerpen, Belgium
    Curr Opin Infect Dis 25:578-83. 2012
    ..Hepatitis A and B vaccines have been commercially available for years; however, the development of the hepatitis E vaccine is still facing some challenges...
  25. pmc Estimating the incidence of symptomatic rotavirus infections: a systematic review and meta-analysis
    Joke Bilcke
    Centre for Health Economics Research and Modeling of Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Wilrijk, Antwerp, Belgium
    PLoS ONE 4:e6060. 2009
    ....
  26. pmc Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study
    Marie Van der Wielen
    The Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
    BMC Fam Pract 11:22. 2010
    ..Although the epidemiology of rotavirus gastroenteritis (RVGE) is well documented, there are few data on the impact of RVGE on the families of affected children...
  27. doi request reprint Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium
    Vaccine 27:454-9. 2009
    ..Intradermal vaccine delivery has been shown to induce good immune responses with low vaccine doses. Technologies for drug-delivery which specifically target the skin may render intradermal vaccination more accessible...
  28. ncbi request reprint Vaccine safety controversies and the future of vaccination programs
    Guido François
    Viral Hepatitis Prevention Board, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerpen, Antwerp, Belgium
    Pediatr Infect Dis J 24:953-61. 2005
    ....
  29. pmc Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study
    Tessa Braeckman
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    BMJ 345:e4752. 2012
    ..To evaluate the effectiveness of rotavirus vaccination among young children in Belgium...
  30. ncbi request reprint Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course
    Koen Van Herck
    Centre for the Evaluation of Vaccination, University of Antwerp, Belgium
    J Med Virol 72:194-6. 2004
    ..This study shows a substantial immune response to re-exposure to hepatitis A antigen after 12 years, which occurs rapidly to ensure protection within the average incubation period of hepatitis A virus...
  31. ncbi request reprint An economic evaluation of varicella vaccination in Italian adolescents
    Nancy Thiry
    Centre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    Vaccine 22:3546-62. 2004
    ..For practical considerations, "anamnestic screening" seems to be the most convenient option...
  32. doi request reprint Rotavirus vaccines in Belgium: policy and impact
    Tessa Braeckman
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 30:S21-4. 2011
    ..Shortly after introduction, a nation-wide recommendation was issued and despite the fact that both rotavirus vaccines are offered through partial reimbursement, vaccine uptake has already reached a high level (at least 90%)...
  33. doi request reprint Timeliness of infant vaccination and factors related with delay in Flanders, Belgium
    Tinne Lernout
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium Electronic address
    Vaccine 32:284-9. 2014
    ....
  34. pmc Sampling site matters when counting lymphocyte subpopulations
    Benson Ogunjimi
    Centre for Health Economics Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    PLoS ONE 7:e41405. 2012
    ..Our findings are crucial for the future design and interpretation of immunological research, and for clinical practice. Furthermore, our results suggest a role for interval lymph nodes in the trafficking of lymphocytes...
  35. doi request reprint Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine
    Koen Van Herck
    Vaccine and Infectious Disease Institute WHO Collaborating Centre, Centre for the Evaluation of Vaccination, Antwerpen, Belgium
    Hum Vaccin Immunother 8:323-7. 2012
    ..This communication provides additional information on antibody persistence up to Year 17 from two of the longest follow-up studies [NCT00289757/NCT00291876]...
  36. doi request reprint Cost-effectiveness of hepatitis A vaccination for adults in Belgium
    Jeroen Luyten
    Centre for Health Economics Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium
    Vaccine 30:6070-80. 2012
    ..5-4 times higher than currently estimated in the general population; or the total costs of vaccination would have to drop with approximately 75%...
  37. doi request reprint Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?
    Joke Bilcke
    Center for Health Economic Research and Modeling Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium
    Vaccine 30:2795-800. 2012
    ..Only one study estimated vaccine efficacy by age at vaccination and time since vaccination combined. Recently, data became available from the same trial for a follow-up period of 7 years...
  38. doi request reprint Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium)
    Eva Lefevere
    Herman Deleeck Centre for Social Policy, Antwerp University, St Jacobstraat 2, Antwerpen, Belgium
    Vaccine 29:8390-6. 2011
    ....
  39. ncbi request reprint Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors
    Marie Van der Wielen
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Control and Prevention of Viral Hepatitis, Unit of Epidemiology and Social Medicine, University of Antwerp, Belgium
    Vaccine 24:5509-15. 2006
    ..In conclusion, Twinrix induced superior hepatitis B SP rates and similar hepatitis A S+ rates compared to concomitant administration of monovalent vaccines in subjects aged >40 years...
  40. ncbi request reprint Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006)
    Froukje Oosterhuis-Kafeja
    University of Antwerp, Antwerp, Belgium
    Vaccine 25:2194-212. 2007
    ..As more and more countries are using these vaccines routinely, post marketing surveillance studies will further establish the safety profile of PCVs...
  41. doi request reprint Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents
    Benson Ogunjimi
    Centre for Health Economics Research and Modeling Infectious Diseases CHERMID, University of Antwerp, Antwerp, Belgium
    Viral Immunol 24:151-7. 2011
    ..One year after initial re-exposure to VZV, VZV-immune adults showed a rise in cellular response as assessed by IFN-γ ELISPOT, and steady-state levels for the humoral response...
  42. doi request reprint Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium
    J Med Virol 81:1710-5. 2009
    ..These results indicate that the removal of preservatives from the hepatitis B vaccine does not affect adversely its immunogenicity both in the short and in the longer term...
  43. doi request reprint Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years
    Koen Van Herck
    Centre for the Evaluation of Vaccination WHO Collaborating Centre, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    J Med Virol 83:1885-91. 2011
    ..No difference in long-term antibody persistence was observed between the two primary vaccination schedules, reinforcing the potential for flexibility in the timing of the second primary vaccine dose...
  44. doi request reprint Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: achieving the best of both worlds
    Tessa Braeckman
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Antwerp, Belgium Electronic address
    Vaccine 32:345-9. 2014
    ..However, further improvement of Vaccinnet's completeness will likely allow more accurate estimates in the nearby future...
  45. doi request reprint What counts in cytometric analysis to document vaccine immunogenicity?
    Benson Ogunjimi
    Centre for Health Economics Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Hum Vaccin Immunother 8:499-500. 2012
    ....
  46. doi request reprint Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory
    Tessa Braeckman
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen Wilrijk, Belgium
    Vaccine 30:4757-61. 2012
    ..We studied the persistence of vaccine-induced anti-HBs antibodies and the robustness of the HBsAg-specific immune memory in this population, 18-20 years after the first vaccine dose...
  47. doi request reprint Hepatitis B and the need for a booster dose
    Elke Leuridan
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Edegem, Belgium
    Clin Infect Dis 53:68-75. 2011
    ..However, a booster dose should be planned for immunocompromised patients, based on serological monitoring...
  48. doi request reprint Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella
    Benson Ogunjimi
    Centre for Health Economics Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Antwerpen, Belgium
    Math Biosci 218:80-7. 2009
    ..Plausible values for R(0) for varicella in Belgium ranged from 7.66 to 13.44. Both approaches based on empirical social contact data provided a better fit to seroprevalence data than the current standard approach...
  49. doi request reprint Benefits of early hepatitis B immunization programs for newborns and infants
    Koen Van Herck
    WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Vaccine, and Infectious Disease Institute, University of Antwerp, Belgium
    Pediatr Infect Dis J 27:861-9. 2008
    ....
  50. ncbi request reprint Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years
    Marie Van der Wielen
    University of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 26:705-10. 2007
    ..The objective of this study was to compare a pediatric dose (0.25 mL) of Epaxal, a virosomal, aluminum-free HAV vaccine, to 0.5 mL standard dose, and to alum-adsorbed HAV vaccine...
  51. ncbi request reprint Hepatitis B vaccination: how to reach risk groups
    Guido François
    Department of Epidemiology and Social Medicine, University of Antwerpen, Universiteitsplein 1, B 2610, Antwerpen, Belgium
    Vaccine 21:1-4. 2002
    ..The VHPB also recognises that new strategies will have to be developed and implemented...
  52. ncbi request reprint Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium)
    Marie Van der Wielen
    Department of Epidemiology and Social Medicine, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
    Vaccine 21:2412-7. 2003
    ..These data confirm waning of vaccine-induced antibody levels and suggest pertussis resurgence during adolescence and young adulthood. These results support a pertussis booster vaccination policy for adolescents and adults...
  53. doi request reprint The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT
    Kevin Lenders
    Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Antwerp University Hospital, Wilrijkstraat 10, B 2650 Edegem, Belgium
    J Immunol Methods 357:51-4. 2010
    ....
  54. doi request reprint Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials
    Pierre Van Damme
    Vaccine and Infectious Disease Institution, University of Antwerp, Wilrijk, Belgium
    Vaccine 29:5932-9. 2011
    ....
  55. ncbi request reprint Prevention of hepatitis A by Havrix: a review
    Koen Van Herck
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
    Expert Rev Vaccines 4:459-71. 2005
    ..In view of this, current regulatory recommendations for the use of hepatitis A vaccines are reviewed and possible future strategies identified...
  56. ncbi request reprint Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections
    Shyama Chatterjee
    Pathology Unit, Department of Medicine, University of Antwerp, Universiteitsplein 1, B 2610 Antwerp, Belgium
    Acta Trop 90:191-203. 2004
    ..This phenomenon is regulated by age whereas gender and prior treatment have no effect on this association. Host specific somatostatin levels may create a 'preset environment' status that can determine progression to severe fibrosis...
  57. ncbi request reprint The prevalence of the human papillomavirus in cervix and vagina in low-risk and high-risk populations
    Marc Baay
    Department of Medical Oncology, University of Antwerp, Antwerp, Belgium
    Scand J Infect Dis 36:456-9. 2004
    ..The high concordance found between HPV prevalence in vagina and cervix warrants further study of the applicability of self-sampling to improve coverage rates by attracting women who would otherwise not obtain a pap test...
  58. doi request reprint Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians
    Benson Ogunjimi
    Centre for Health Economics Research and Modeling Infectious Diseases CHERMID, Vaccine and Infectious Disease Institute VAXINFECTIO, University of Antwerp, Antwerp, Belgium
    Clin Vaccine Immunol 21:417-26. 2014
    ..Repetitive exposures to VZV have been shown to induce a stable increased level of VZV-specific cellular but not humoral immunity. Based on our observations, VZV IE63 can be considered a candidate for a zoster vaccine. ..
  59. ncbi request reprint Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey
    Heidi Theeten
    Centre for the Evaluation of Vaccination, University of Antwerp, Universiteitsplein 1, B 2610 Antwerp, Belgium
    Vaccine 25:4940-8. 2007
    ....
  60. ncbi request reprint Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006)
    Philippe Beutels
    Centre for the Evaluation of Vaccination, Epidemiology and Social Medicine, University of Antwerp Campus Drie Eiken, Universiteitsplein 1, 2610 Antwerp, Belgium
    Vaccine 25:1355-67. 2007
    ....
  61. ncbi request reprint Long-term protection after hepatitis A and B vaccination: an update
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp
    Acta Gastroenterol Belg 66:247-9. 2003
  62. doi request reprint Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants
    Elke Leuridan
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, WHO Collaborating Centre for Control and Prevention of Infectious Diseases, Faculty of Medicine, University of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 30:608-10. 2011
    ....
  63. doi request reprint Lessons learned from a measles outbreak in Antwerp, Belgium 2007-2008
    Carine Asnong
    School Health Center of the Province of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 30:343-5. 2011
    ..Not only belief issues but difficulties to access the regular vaccination program also seem to be the main reason...
  64. doi request reprint Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines
    Vanessa Vankerckhoven
    University of Antwerp, Vaccine and Infectious Disease Institute, Center for Evaluation of Vaccination, Universiteitsplein 1, Antwerp Wilrijk, Belgium
    Expert Opin Drug Deliv 7:1109-25. 2010
    ..In addition, higher immune responses with the same quantity of antigen have been elicited with intradermal vaccine administration, offering dose-sparing capacity...
  65. ncbi request reprint Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults
    Pierre Van Damme
    Center for the Evaluation of Vaccination, University of Antwerp, Belgium
    Hum Vaccin 5:92-7. 2009
    ....
  66. ncbi request reprint Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001
    Pierre Van Damme
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis, Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium
    J Med Virol 67:433-9. 2002
    ..In Europe, as well as in the rest of the world, work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to eradicate hepatitis B...
  67. pmc Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults
    Pierre Van Damme
    Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    PLoS ONE 6:e25398. 2011
    ..We report the results from a Phase 1 and a Phase 2 dose ranging trial with Vi-CRM₁₉₇ in European adults...
  68. ncbi request reprint Economic evaluations of varicella vaccination programmes: a review of the literature
    Nancy Thiry
    Department of Epidemiology and Social Medicine, Centre for the Evaluation of Vaccination, University of Antwerp, Antwerp, Belgium
    Pharmacoeconomics 21:13-38. 2003
    ..Since violation of these assumptions could have important adverse public health effects, we suggest pre-adolescent vaccination as a more secure alternative. This option deserves more attention in future analyses...
  69. ncbi request reprint Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines
    Heidi Theeten
    University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium
    Curr Med Res Opin 23:2729-39. 2007
    ....
  70. ncbi request reprint Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study
    Koen Van Herck
    Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis Epidemiology and Social Medicine, University of Antwerp, Universiteitsplein 1, B 2610 Antwerp, Belgium
    J Travel Med 10:75-8. 2003
    ....
  71. ncbi request reprint Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts
    Heinz J Schmitt
    Paediatric Infectious Diseases, Epidemiology and Vaccine Development, Centre for Preventive Paediatrics, Johannes Gutenberg University, Mainz, Germany
    Lancet Infect Dis 3:103-8. 2003
    ..The system as well as the schedule used would then be of minor importance...
  72. ncbi request reprint Immunisation information for parents
    Diana Steimle
    European Vaccine Manufacturers, Brussels, Belgium
    Nurs Stand 16:40-4. 2002
    ..The authors examine the benefits of childhood immunisation and this information could be used by nurses when advising parents...
  73. ncbi request reprint Combined hepatitis B vaccines
    David FitzSimons
    World Health Organization, Via Appia 20, 1211 Geneva, Switzerland
    Vaccine 21:1310-6. 2003
    ..Finally, the impact of the availability of combined hepatitis B vaccines on hepatitis B immunisation programmes in Europe were examined and the added value of combined hepatitis B vaccines globally was estimated...
  74. ncbi request reprint Hepatitis A vaccine
    Koen Van Herck
    N Engl J Med 350:2211-2; author reply 2211-2. 2004
  75. ncbi request reprint Methodological issues and new developments in the economic evaluation of vaccines
    Philippe Beutels
    National Center for Immunisation Research and Surveillance, University of Sydney and Center for Health Economics Research and Evaluation, Australia
    Expert Rev Vaccines 2:649-60. 2003
    ..Developments in the next 5 years are likely to address all of these issues and result in more sophisticated and accurate models of vaccination programs...
  76. ncbi request reprint Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use
    Francis Andre
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 1:9-23. 2002
    ..Existing official recommendations and future directions for vaccine use are reviewed...
  77. ncbi request reprint Epidemiology of hepatitis C in Belgium: present and future
    Pierre Van Damme
    Epidemiologie en Sociale Geneeskunde, Centrum voor de Evaluatie van Vaccinaties, Universitaire Instelling Antwerpen
    Acta Gastroenterol Belg 65:78-9. 2002
    ..Techniques detecting hepatitis C antibodies in saliva will replace the need for serum samples, making prevalence studies more accessible...
  78. ncbi request reprint Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study
    Carlo Giaquinto
    Department of Pediatrics, University of Padua, Padua, Italy
    J Infect Dis 195:S26-35. 2007
    ..The availability of comprehensive, up-to-date epidemiologic data would improve the understanding of the disease burden and clinical consequences of rotavirus gastroenteritis (RVGE) in Europe...
  79. ncbi request reprint Combined hepatitis A and B vaccine in elderly
    Pierre Van Damme
    Vaccine 22:303-4. 2004
  80. ncbi request reprint Rapid protection and vaccination against hepatitis A for travellers
    Bradley A Connor
    The New York Center for Travel and Tropical Medicine, New York, NY 10021, USA
    BioDrugs 17:19-21. 2003
  81. ncbi request reprint A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium
    Sophie Quoilin
    Unit of Epidemiology, Scientific Institute of Public Health, Juliette Wytsmanstreet 14, 1050 Brussels, Belgium
    Eur J Epidemiol 22:195-202. 2007
    ..Considering the 30% response rate and the high quality of the self-collected samples as reflect of a good participation of the general population, saliva test for prevalence study is a good epidemiological monitoring tool...
  82. ncbi request reprint Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL Study
    Carlo Giaquinto
    Department of Pediatrics, University of Padua, Padua, Italy
    J Infect Dis 195:S36-S44. 2007
    ..Morbidity and resource use due to rotavirus gastroenteritis (RVGE) are substantial in Europe, although comprehensive data on the economic impact of the disease are lacking...
  83. ncbi request reprint Prevention and control of viral hepatitis through adolescent health programmes in Europe
    David FitzSimons
    World Health Organization, Via Appia 20, CH 1211 Geneva, Switzerland
    Vaccine 25:8651-9. 2007
    ..The meeting concluded with a discussion of issues, lessons learnt, opportunities and action points for the future...
  84. doi request reprint Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants
    Corinne Vandermeulen
    Center for Youth Health Care, Katholieke Universiteit Leuven, Kapucijnenvoer 35, B 3000 Leuven, Belgium
    Pediatrics 121:e428-34. 2008
    ..The objective of this study was to measure the coverage and influencing determinants of hepatitis B virus, measles-mumps-rubella, and Meningococcus serogroup C vaccination in 14-year-old adolescents in Flanders, Belgium, in 2005...
  85. doi request reprint Rotavirus
    Jim Gray
    Centre for Infections, Health Protection Agency, London, UK
    J Pediatr Gastroenterol Nutr 46:S24-31. 2008
  86. doi request reprint European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    J Pediatr Gastroenterol Nutr 46:S38-48. 2008
  87. doi request reprint European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary
    Timo Vesikari
    Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland
    J Pediatr Gastroenterol Nutr 46:615-8. 2008
  88. ncbi request reprint The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination
    Hans Dieter Nothdurft
    Department of Infectious Diseases and Tropical Medicine, University of Munich, Munich, Germany
    J Travel Med 14:181-7. 2007
  89. pmc Hepatitis B immunisation in Britain: time to change?
    Jangu Banatvala
    BMJ 332:804-5. 2006
  90. ncbi request reprint Prevention of viral hepatitis in Italy
    David FitzSimons
    World Health Organization, 1211 Geneva, Switzerland
    Vaccine 22:4092-6. 2004
    ..Several specific conclusions, drawn from the presentations and discussions, were considered to constitute an example of how to handle these issues in other European and industrialized countries...
  91. ncbi request reprint Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 354:23-33. 2006
    ..Rotavirus is a leading cause of childhood gastroenteritis and death worldwide...
  92. ncbi request reprint Effect of hepatitis A vaccination programs
    Pierre Van Damme
    JAMA 294:246-8. 2005
  93. ncbi request reprint Immunisation in the current management of cystic fibrosis patients
    Anne Malfroot
    Department of Paediatrics, Paediatric Respiratory Medicine, Infectious Diseases and Cystic Fibrosis Clinic, Academisch Ziekenhuis Vrije Universiteit Brussel AZ VUB, Laarbeeklaan 101, B 1090 Brussels, Belgium
    J Cyst Fibros 4:77-87. 2005
    ..More studies are needed to complete recommendations especially for CF adults and transplant candidates...
  94. ncbi request reprint Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers
    Hans D Nothdurft
    Department of Infectious Diseases and Tropical Medicine, Ludwig Maximilians University, Munich, Germany
    J Travel Med 11:260-1. 2004
  95. ncbi request reprint Can health programmes lead to mistreatment of sex workers?
    Pierre Van Damme
    Lancet 362:328-9. 2003
  96. ncbi request reprint Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant
    Isabelle Desombere
    Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185 9000, Ghent, Belgium
    Vaccine 20:2597-602. 2002
    ..The HBsAg/AS04 vaccine was more reactogenic mainly because of an increased local reactogenicity. Both vaccines, especially HBsAg/AS04, are highly immunogenic and well tolerated by the study subjects...
  97. ncbi request reprint Effectiveness of seven-valent pneumococcal conjugate vaccine
    Philippe Beutels
    Lancet 369:460; author reply 460. 2007
  98. ncbi request reprint Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial
    Leon Heron
    National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Childrens Hospital, Westmead, Australia
    Vaccine 25:2817-22. 2007
    ..Both regimens were shown to be safe and well tolerated. Two doses of Engerix-B (20 microg HBsAg) could be considered as an alternative to standard three-dose Engerix-B (10 microg HBsAg) immunisation for adolescents aged 11-15 years...
  99. ncbi request reprint Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells
    Viktor Prikazsky
    Slovak National Commission for Certification of the Polio Eradication, Partizanska 3261, SK 05801 Poprad, Slovakia
    Vaccine 23:4219-27. 2005
    ..Excretion rates and prevalence of revertants for the three serotypes following vaccination were also similar for both vaccines. These data support the use of MRC-5 cells as an alternative to PMKC for OPV production...
  100. pmc Vaccine induced protection against hepatitis B
    Pierre Van Damme
    BMJ 326:105. 2003
  101. ncbi request reprint Oral fluid as a medium for the detection of hepatitis B surface antigen
    Veronik Hutse
    Unit of Epidemiology, Scientific Institute of Public Health, Brussels, Belgium
    J Med Virol 77:53-6. 2005
    ..7% and 100%, respectively. The modified ETI-MAK-4 ELISA is a suitable test for oral fluid samples collected by the Oracol collection device for epidemiological purposes...